Integrative Study Conducted by 10x Genomics Combines Single Cell, Spatial and In Situ Analyses to Investigate Tumor Invasiveness
- None.
- None.
10x Genomics' recent publication in Nature Communications represents a significant advancement in cancer research, particularly in the understanding of breast cancer tumor microenvironments. The study's innovative integration of single-cell genomics and spatial biology technologies can potentially lead to more precise diagnostic and therapeutic strategies, which is critical for personalized medicine.
The use of the Chromium Single Cell, Visium Spatial and Xenium In Situ platforms to dissect the heterogeneity of a tumor microenvironment is a testament to the company's leading edge in the biotechnology sector. The ability to identify spatially distinct tumor regions and a previously undetectable triple-positive receptor region signifies a leap forward in tumor profiling accuracy.
From an investment perspective, such technological advancements by 10x Genomics may enhance its competitive edge and could lead to increased demand for its products. Moreover, the potential for these platforms to contribute to earlier detection and more targeted treatment of cancers may drive long-term growth for the company.
The detailed analysis of tumor microenvironments by 10x Genomics could usher in a new era of precision oncology. The study's findings underscore the limitations of traditional pathological assessments and highlight the necessity for comprehensive molecular profiling. By uncovering sub-regions within tumors that exhibit distinct cellular compositions and gene expressions, this research paves the way for more nuanced therapeutic approaches.
For clinicians and researchers, the implications are profound. The ability to detect subtle microenvironmental variations within tumors could lead to more effective treatments, tailored to the specific cellular makeup of each patient's cancer. This could improve patient outcomes and potentially reduce the cost of treatment by minimizing ineffective therapies.
The publication of this study by 10x Genomics may have a considerable impact on the healthcare industry, particularly in the field of oncology diagnostics. The findings provide a compelling case for the adoption of advanced spatial profiling techniques in routine cancer pathology, which could lead to a paradigm shift in disease diagnosis and treatment planning.
As a result, there may be a growing market for 10x Genomics' platforms, which could attract further investment into the sector. Healthcare providers and diagnostic laboratories may need to adapt to these new technologies, potentially driving a wave of innovation and collaboration across the industry. The long-term benefits could include more accurate diagnoses, personalized treatment regimens and ultimately, improved patient care.
A team of 10x Genomics scientists conducted a comprehensive analysis of human breast tumor microenvironments using all three of its industry-leading platforms
In this study, "High resolution mapping of the tumor microenvironment using integrated single-cell, spatial and in situ analysis," the 10x scientists sought to untangle the complex heterogeneity of the tumor microenvironment of a formalin-fixed paraffin-embedded (FFPE) breast cancer block using independent but complementary technologies. The peer-reviewed publication, which is now available in Nature Communications, refines and builds on work previously posted in bioRxiv in late 2022.
The researchers first defined the cellular composition of the sample using Chromium Single Cell Gene Expression Flex (Chromium scFFPE-seq), which yields highly sensitive whole transcriptome data. Since this profiling is performed on FFPE sections from the same block assessed via pathology and spatial profiling, the Chromium Flex data is a more precise representation of the tissue biology observed with those methods than dissociated tumor cells from the same patient. To determine where the various cell types in the sample reside in the tumor microenvironment, the team performed whole transcriptome Visium CytAssist Spatial Gene Expression profiling on an adjacent tissue section. Visium analysis was able to identify three spatially distinct tumor regions. Lastly, the team used the single cell spatial resolution of Xenium In Situ to more precisely map complex regions of the tumor where multiple cell types were present in very close proximity. Importantly, this high-resolution spatial view of the sample identified a tiny region expressing three receptors commonly used for diagnosis of a breast cancer subtype, which otherwise would have gone unnoticed.
In addition to this groundbreaking approach demonstrating the strengths of each platform, it also showcases the power of integrating the findings. For example, integration of the Chromium and Visium data enabled the three spatially distinct tumor domains to be correlated with specific clusters and differentially expressed genes, while Xenium provided the cell-type composition of the domains. Furthermore, after pinpointing the triple-positive receptor region in the sample in the Xenium data, the team was able to reexamine this region within the Visium data to assess differences in cellular composition and gene expression.
Sarah Taylor, Senior Director of Applications at 10x Genomics, said, "This study was only possible due to the complementarity that exists between our platforms. The shared sample compatibility allowed us to process sections from the same FFPE sample with all three workflows, while the synergies of the technologies and software solutions made the data integration simple. Critically, it was the integration of this data that allowed us to understand the unique cancer biology occurring in the sample with more rigor and refinement than using any single technology alone."
"This study also illuminates the value of supplementing traditional pathological analysis with the more detailed molecular profiling capabilities of spatial profiling techniques," said Amanda Janesick, first author and a Senior Scientist on the 10x Genomics Applications Team. "For example, the three spatially distinct tumor regions identified by Visium and the small triple-positive receptor region detected by Xenium were not initially noted via pathological assessment. In a second breast cancer sample assessed by Xenium, the data picked up tumor cell markers in regions pathologically annotated as having normal duct morphology. These findings highlight that spatial profiling methods may provide valuable clues into disease biology and progression before any notable morphological changes could be detected by current methods and tools for pathology."
To learn more about this study, read the full article.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/integrative-study-conducted-by-10x-genomics-combines-single-cell-spatial-and-in-situ-analyses-to-investigate-tumor-invasiveness-302018566.html
SOURCE 10x Genomics, Inc
FAQ
What did 10x Genomics announce?
What is the title of the study published by 10x Genomics?
What platforms did 10x Genomics use in the study?
Who is Sarah Taylor?
What value does the study illuminate?
